A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis

Dermatologic Surgery

Volumn 33, Issue SUPPL. 1, 2007, Pages

  Talarico Filho, Sérgio ^a,b   Mendonça Do Nascimento, Maurício ^a   Sperandeo De Macedo, Fernando ^a   De Sanctis Pecora, Carla ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTICLE; AXILLA; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE INTERVAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRAVIMETRY; HUMAN; HYPERHIDROSIS; MALE; MUSCLE DISEASE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; SWEAT TEST; SWEATING; SYSTEMIC DISEASE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AXILLA; BOTULINUM TOXIN TYPE A; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERHIDROSIS; INJECTIONS; MALE; MIDDLE AGED; SWEATING;

EID: 33845995864     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2006.32331.x     Document Type: Article

References (22)

1. Heckman M, Breit S, Ceballos-Bauman A, et al. Side-controlled intradermal injection of botulinum toxin A in recalcitrant axillary hyperhidrosis. J Am Acad Dermatol 1999;41:987-90.
2. Freeman R, Waldorf HA, Dover JS. Autonomic neurodermatology (Part II): disorders of sweating and flushing. Semin Neurol 1992;12:394-407.
3. Maillard H, Briand N, Bara C, Celerier P. Efficacy of botulinum toxin in the treatment of axillary and palmar hyperhidrosis: 10 cases. Ann Dermatol Venereol 2003;130:511-3.
4. Buchara KO, Park DM, Jones SC, Schutta HS. Botulinum toxin: a possible new treatment for axillary hyperhidrosis. Clin Exp Dermatol 1996;21:276-8.
5. Zacherl J, Huber ER, Imhof M. Long-term results of 630 thoracoscopic sympathicotomies for primary hyperhidrosis: the Vienna experience. Eur J Surg Suppl 1988;43-6.
6. Charles PD. Botulinum neurotoxin serotype A: a clinical update on non-cosmetic uses. Am J Health Syst Pharm 2004;61:S11-S23.
7. Schnider P, Binder M, Auff E, et al. Double-blind trial of botulinum A toxin for treatment of focal hyperhidrosis of palms. Br J Dermatol 1997;135:548-52.
8. Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ 2001;15: 596-9.
9. Schnider P, Binder M, Kittler H, et al. A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis. Br J Dermatol 1999;140:677-80.
10. Odderson IR. Long-term quantitative benefits of botulinum toxin type A in the treatment of axillary hyperhidrosis. Dermatol Surg 2002;28:480-3.
11. Naumann M, Lowe NJ, Kumar CR, et al. Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol 2003;139: 731-6.
12. Heckmann M, Ceballos-Baumann AO, Plewig G. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 2001;15:488-99.
13. Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol 2003;149:1041-5.
14. Hesse S, Brandi-Hesse B, Bardeleben A, et al. Botulinum toxin A treatment of adult upper and lower limb spasticity. Drugs Aging 2001;18:255-62.
15. Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomized, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998;64:6-12.
16. Marion MH, Sheehy M, Sangla S, Soulayrol S. Dose standardization of botulinum toxin. J Neurol Neurosurg Psychiatry 1995;59:102-3.
17. Whurr R, Brookes G, Barnes C. Comparison of dosage effects between the American and British botulinum toxin A product in the treatment of spasmodic dysphonia. Mov Disord 1995;10:56.
18. Ranoux D, Gury C, Fonadarai J, et al. Respective potencies of Botox and Dysport: a double blind, randomized, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72:459-62.
19. Lowe NJ. Botulinum toxin type A for facial rejuvenation: United States and United Kingdom perspectives. Dermatol Surg 1998;24:1216-8.
20. Sampaio C, Ferreira JJ, Simões F, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A - Dysport and Botox - assuming a ratio of 4:1. Mov Disord 1997;12:1013-8.
21. Lowe PL, Cerdan-Sanz S, Lowe NJ. Botulinum toxin type A in the treatment of bilateral primary axillary hyperhidrosis: efficacy and duration with repeated treatments. Dermatol Surg 2003;29:545-8.
22. Schnider P, Moraru E, Kittler H, et al. Treatment of focal hyperhidrosis with botulinum toxin type A. long-term follow-up in 61 patients. Br J Dermatol 2001;145:289-93.